Involvement of nitric oxide pathway in the acute anticonvulsant effect of salmon calcitonin in rats

Epilepsy Res. 2022 Feb:180:106864. doi: 10.1016/j.eplepsyres.2022.106864. Epub 2022 Jan 19.

Abstract

Epilepsy is a chronic neurological disease that is thought to affect up to 1% of the world's population. Evidence suggests that salmon calcitonin (sCT) has positive effects on epileptic seizures and epileptogenesis. However, it remains unknown that whether nitric oxide (NO) pathway contributed to this antiepileptic effect of sCT. We have used the pentylenetetrazole (PTZ)-induced seizure rat model to identify the effect of sCT on seizure score, seizure-induced cognitive deficit, and the NO pathway in the brain. We found that sCT increases the first myoclonic jerk (FMJ), decreased Racine's convulsion scale (RCS), and abates seizure-induced cognitive impairment. We further demonstrated that sCT attenuated the abnormal increase of NO in the brain. These results revealed that sCT exerts an antiepileptic effect by modulating the NO pathway in the brain.

Keywords: Neuroinflammation; Nitric oxide; Pentylenetetrazole; Rat; Salmon calcitonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants* / pharmacology
  • Anticonvulsants* / therapeutic use
  • Calcitonin
  • Disease Models, Animal
  • Electroencephalography
  • Nitric Oxide*
  • Pentylenetetrazole / toxicity
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Anticonvulsants
  • Nitric Oxide
  • salmon calcitonin
  • Calcitonin
  • Pentylenetetrazole